Zacks Investment Research cut shares of Cooper Companies, Inc. (The) (NYSE:COO) from a buy rating to a hold rating in a research note released on Wednesday.

According to Zacks, “The Cooper Companies has had an impressive run on the bourse over the last six months. The company has seen strong growth at its CooperVision business segment of late. Notably, the segment banks on the platforms of MyDay, Clariti and Biofinity silicone hydrogel lenses. The CooperSurgical segment also delivered strong sales in the quarter. A strong guidance for fiscal 2017 instills our confidence on the stock. Cooper Companies has completed the acquisition of Procornea in the recent past. This added a leading ortho-k technology to Cooper Company’s lens portfolio and marked its foray in the emerging myopia controlled markets. However, the dampening outlook for the CooperSurgical segment indicates looming concerns. Furthermore, intensifying competition in the contact-lens space will continue to increase pricing pressure. Added to this, escalating debt levels and foreign exchange vulnerability are likely to mar the company;s bottom line.”

Several other equities research analysts have also commented on COO. Jefferies Group LLC set a $250.00 price objective on Cooper Companies, Inc. (The) and gave the stock a buy rating in a research note on Thursday, August 17th. Cleveland Research reiterated a buy rating on shares of Cooper Companies, Inc. (The) in a research note on Tuesday, August 22nd. BidaskClub lowered Cooper Companies, Inc. (The) from a buy rating to a hold rating in a research note on Friday, August 4th. Robert W. Baird set a $273.00 price target on Cooper Companies, Inc. (The) and gave the stock a buy rating in a research note on Monday, October 16th. Finally, KeyCorp reiterated a hold rating on shares of Cooper Companies, Inc. (The) in a research note on Friday, October 20th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Cooper Companies, Inc. (The) has an average rating of Buy and a consensus target price of $261.11.

Cooper Companies, Inc. (The) (NYSE:COO) last posted its quarterly earnings data on Thursday, August 31st. The medical device company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.58 by $0.06. The firm had revenue of $556.00 million during the quarter, compared to analyst estimates of $552.32 million. Cooper Companies, Inc. (The) had a return on equity of 16.00% and a net margin of 16.45%. Cooper Companies, Inc. (The)’s revenue was up 8.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.30 EPS.

ILLEGAL ACTIVITY NOTICE: “Cooper Companies, Inc. (The) (COO) Downgraded to “Hold” at Zacks Investment Research” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/cooper-companies-inc-the-coo-downgraded-to-hold-at-zacks-investment-research/1674208.html.

In other news, Director Gary S. Petersmeyer sold 3,977 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $244.94, for a total transaction of $974,126.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.60% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Advisory Services Network LLC grew its position in shares of Cooper Companies, Inc. (The) by 30.6% during the second quarter. Advisory Services Network LLC now owns 457 shares of the medical device company’s stock valued at $109,000 after purchasing an additional 107 shares in the last quarter. YorkBridge Wealth Partners LLC grew its position in shares of Cooper Companies, Inc. (The) by 2.1% during the second quarter. YorkBridge Wealth Partners LLC now owns 531 shares of the medical device company’s stock valued at $126,000 after purchasing an additional 11 shares in the last quarter. Acrospire Investment Management LLC grew its position in shares of Cooper Companies, Inc. (The) by 50.0% during the second quarter. Acrospire Investment Management LLC now owns 600 shares of the medical device company’s stock valued at $144,000 after purchasing an additional 200 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Cooper Companies, Inc. (The) during the third quarter valued at about $163,000. Finally, Visionary Asset Management Inc. purchased a new position in shares of Cooper Companies, Inc. (The) during the second quarter valued at about $201,000. Hedge funds and other institutional investors own 95.26% of the company’s stock.

About Cooper Companies, Inc. (The)

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Analyst Recommendations for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.